{"preliminary_commentary":{"by_channel":{"x_thread":196,"youtube":170,"podcast":131,"bluesky_thread":16,"x_video":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04494425\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T04:12:01.907Z","note":"Automated from the 40 newest of 517 indexed sources (May 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- How to sequence trastuzumab deruxtecan with other antibody–drug conjugates\n- Whether to use chemotherapy or an antibody–drug conjugate after endocrine therapy\n- How trastuzumab deruxtecan compares with newer antibody–drug conjugates\n\nAlso discussed: antibody–drug conjugate toxicity profiles, HER2 testing and expression heterogeneity."},"drugs_tested":[["trastuzumab deruxtecan"]],"indication":"hormone receptor-positive HER2-low or HER2-ultralow metastatic breast cancer","name":"DESTINY-Breast06","nct_id":"NCT04494425","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast06-nct04494425. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DB-06","arms":[{"description":"Trastuzumab deruxtecan (T-DXd; DS-8201a) arm","label":"Trastuzumab deruxtecan","type":"EXPERIMENTAL"},{"description":"Investigator's choice standard of care chemotherapy (capecitabine, paclitaxel, nab-paclitaxel) arm","label":"Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2026-06-19","type":"ESTIMATED"},"conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":{"count":866,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a; T-DXd"],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Nab-Paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-04","lead_sponsor":"AstraZeneca","official_title":"A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population","timeFrame":"Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)"}],"references":[{"citation":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Levy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15.","pmid":"39282896","type":"DERIVED"},{"citation":"Tarantino P, Tolaney SM, Curigliano G. Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. Ann Oncol. 2023 Oct;34(10):949-950. doi: 10.1016/j.annonc.2023.07.003. Epub 2023 Jul 26. No abstract available.","pmid":"37499870","type":"DERIVED"}],"start_date":{"date":"2020-07-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04494425"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast06-nct04494425"}